Zobrazeno 1 - 10
of 144
pro vyhledávání: '"VCG Tjan-Heijnen"'
Autor:
E.J. Kuip, Iam Mandjes, M. Jonge-Lavrencic, CP Schroeder, M. J. Holtkamp, Inge R. H. M. Konings, Judith R. Kroep, J. P. Lotz, Ulrike Nitz, M.N. Wymenga, Anthony Gonçalves, M. Graeser, Sabine C. Linn, Margaret Schot, Agnes Jager, Valesca P. Retèl, E. E. van der Wall, S.B. Vliek, Vcg Tjan-Heijnen
Publikováno v:
Cancer Research. 78:OT2-07
Background: An intact homologous repair (HR) pathway is essential for error-free repair of DNA double strand breaks (DSB). Preclinical and clinical data have shown that breast cancer (BC) cells with a defect in the HR pathway are a target for DNA DSB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4223e45c3011c9c39415d163caff4991
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-08
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-08
Autor:
A Jager, M Jongen-Lavrencic, JP Lotz, A Gonçalves, M Graeser, U Nitz, IAM Mandjes, MJ Holtkamp, M Schot, VP Retel, EJ Kuip, ANM Wymenga, IR Konings, VCG Tjan-Heijnen, JR Kroep, CP Schrӧder, E Van Der Wall, Sc Linn, S Vliek
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3389d18e6873ca9ee30fb022f95fc593
Autor:
Ann Hoeben, Nicolien Kasperts, Sandra M. E. Geurts, Vcg Tjan-Heijnen, Pètra M. Braam, J. de Vos-Geelen, Heike I. Grabsch, G.A.P. Nieuwenhuijzen, G.J. Blom, Tom Rozema, Paul M. Jeene, B. T. A. de Greef, Francine E.M. Voncken, M.A. de Jong, V.E.P.P. Lemmens, J.A. Bogers, H.W.M. van Laarhoven, Frank J. P. Hoebers, Maarten C.C.M. Hulshof, Christina T. Muijs
Publikováno v:
Annals of Oncology. 30:v295
Background Proximal oesophageal cancer is commonly treated with definitive chemoradiation (CRT). The radiation dose and type of chemotherapy backbone in CRT are still under debate. The objective of this study is to compare the treatment benefit of fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1064b7fabaa449820f0d1c1556624dd4
https://doi.org/10.1093/annonc/mdz247.087
https://doi.org/10.1093/annonc/mdz247.087
Autor:
F.P.J. Peters, Pgm Peer, M.W. Dercksen, Tineke J. Smilde, Jmgh van Riel, Najb Peters, M. de Boer, F.W.P.J. van den Berkmortel, Dja Lobbezoo, Adri C. Voogd, Vcg Tjan-Heijnen, A.J. van de Wouw, Rjw van Kampen
Publikováno v:
Cancer Research. 73:P3-13
Introduction Treatment of patients with metastatic breast cancer (MBC) generally has a palliative intent. The systemic treatment approach is based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. However, with a va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7b7c990f0ab5bb56d01fe5259989d76
https://doi.org/10.1158/0008-5472.sabcs13-p3-13-11
https://doi.org/10.1158/0008-5472.sabcs13-p3-13-11
Autor:
Vcg Tjan-Heijnen, Rjw van Kampen, M.W. Dercksen, Pgm Peer, Dja Lobbezoo, Adri C. Voogd, A.J. van de Wouw, F.W.P.J. van den Berkmortel
Publikováno v:
Cancer Research. 73:P3-06
Background Adjuvant systemic therapy choices in early breast cancer largely depend on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Overexpression of HER2 has been shown to be associated with a worse outcome (Slamo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dd34e4c73d86fb5205a3e6ae39608b5
https://doi.org/10.1158/0008-5472.sabcs13-p3-06-05
https://doi.org/10.1158/0008-5472.sabcs13-p3-06-05
Autor:
Shanly C. Seferina, Manuela A. Joore, A.J. van de Wouw, Rjw van Kampen, F.W.P.J. van den Berkmortel, Vcg Tjan-Heijnen, M.W. Dercksen, George F. Borm, Dja Lobbezoo, Adri C. Voogd
Publikováno v:
Cancer Research. 72:P5-21
Background The impact of drug prescriptions in the real world as opposed to strict trial prescription is only rarely assessed even though it is well recognized that incorrect use may harm a patient and may have a huge impact on health care resources.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1838d522a2f1edb1d223028e819a862
https://doi.org/10.1158/0008-5472.sabcs12-p5-21-04
https://doi.org/10.1158/0008-5472.sabcs12-p5-21-04
Autor:
J. Wals, L. J. C. van Warmerdam, H.W.M. van Laarhoven, George F. Borm, Birgit E.P.J. Vriens, D.J. van Spronsen, Tineke J. Smilde, S. M. van Gastel, B. de Vries, Vcg Tjan-Heijnen
Publikováno v:
Cancer Research. 72:P1-14
Background Taxanes have an established role as (neo-)adjuvant treatment of breast cancer. In the present study, we compared 4 AC–4 T with 6 cycles of TAC in the neoadjuvant setting (A = adriamycine, C = cyclophosphamide, T = docetaxel). Previously,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6024c95491a4b96ce7224c6387c146b
https://doi.org/10.1158/0008-5472.sabcs12-p1-14-07
https://doi.org/10.1158/0008-5472.sabcs12-p1-14-07
Autor:
Vcg Tjan-Heijnen, Sabine Siesling, Alm Verbeek, Sme Geurts, Vegt F de, Y. Paquay, Dijck Jaam van
Publikováno v:
Cancer Research. 71:P1-08
Introduction The purpose of this study was to evaluate the dwindling risk of relapse in breast cancer patients treated with curative intent since the 1970s. Patients and methods 8570 women diagnosed with invasive breast cancer in 2003 or 2004 were co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9739ed9a713b183247cb86ab8653972b
https://doi.org/10.1158/0008-5472.sabcs11-p1-08-03
https://doi.org/10.1158/0008-5472.sabcs11-p1-08-03
Autor:
Sabine Siesling, Abg Kwast, I. Grandjean, Mbe Menke-Pluymers, Vcg Tjan-Heijnen, V.K.Y. Ho, der Sangen Mjc van
Publikováno v:
Cancer Research. 71:P1-08
Introduction: Many studies investigated disease free survival after breast cancer treatment. A few studies focused on patterns of recurrence risk over time. However, they ignored the impact of histology. This study aimed to determine differences in r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a2d60e9733d06cd3c26e5a0789a783a
https://doi.org/10.1158/0008-5472.sabcs11-p1-08-11
https://doi.org/10.1158/0008-5472.sabcs11-p1-08-11
Autor:
Ccd van der Rijt, Wmw Dercksen, Mjb Aarts, Yjl Kamm, Hwr Nortier, S. M. van Gastel, Alphons G.H. Kessels, Ljc van Warmerdam, Cmpw Mandigers, Manuela A. Joore, Vcg Tjan-Heijnen, Jacqueline M. Stouthard, F.P.J. Peters
Publikováno v:
Cancer Research. 70:P3-15
Background: In patients at risk of febrile neutropenia (FN), the highest incidence of FN is seen during the first chemotherapy cycles. This observation questions the effectiveness of continued G-CSF prophylaxis during later chemotherapy cycles. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0cb4b1ffebc98269b63124f9c2021a6
https://doi.org/10.1158/0008-5472.sabcs10-p3-15-01
https://doi.org/10.1158/0008-5472.sabcs10-p3-15-01